Although its prognostic role in gastric cancers is unclear, HER2 was the first routinely targeted biomarker in gastric cancers and, until the relatively recent advent of immunotherapy in gastrointestinal cancers, the only biomarker with implications on the clinical management of this disease. This evidence concerns the gene ERBB2 and gastric cancer.